Myocardial Vasculitis Associated With the Immune Checkpoint Inhibitor Pembrolizumab

Hideo Oishi, MD; Ryota Morimoto, MD, PhD; Yoshie Shimoyama, MD, PhD; Kei Kuroda, MD; Toru Urata, MD; Toru Kondo, MD, PhD; Takahiro Okumura, MD, PhD; Yasuko K. Bando, MD, PhD; Masashi Akiyama, MD, PhD; Toyoaki Murohara, MD, PhD

JACC: Case Reports (Oct 2020)

Myocardial Vasculitis Associated With the Immune Checkpoint Inhibitor Pembrolizumab

Hideo Oishi, MD,
Ryota Morimoto, MD, PhD,
Yoshie Shimoyama, MD, PhD,
Kei Kuroda, MD,
Toru Urata, MD,
Toru Kondo, MD, PhD,
Takahiro Okumura, MD, PhD,
Yasuko K. Bando, MD, PhD,
Masashi Akiyama, MD, PhD,
Toyoaki Murohara, MD, PhD

Affiliations

Hideo Oishi, MD: Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Ryota Morimoto, MD, PhD: Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan; Address for correspondence: Dr. Ryota Morimoto, Department of Cardiology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan.
Yoshie Shimoyama, MD, PhD: Department of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Kei Kuroda, MD: Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Toru Urata, MD: Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Toru Kondo, MD, PhD: Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Takahiro Okumura, MD, PhD: Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Yasuko K. Bando, MD, PhD: Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Masashi Akiyama, MD, PhD: Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Toyoaki Murohara, MD, PhD: Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan

Journal volume & issue: Vol. 2, no. 12
pp. 1937 – 1941

Abstract

Read online

Recent developments in immune checkpoint inhibitors (ICIs) have provided new treatment strategies for advanced cancer. However, ICIs lead to an imbalance between T cell–mediated inflammatory responses and immune tolerance in the myocardium. Here we report the first case that implicates the contribution of ICI-induced vasculitis to myocardial injury. (Level of Difficulty: Intermediate.)

Published in JACC: Case Reports

ISSN: 2666-0849 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the circulatory (Cardiovascular) system
Website: https://www.journals.elsevier.com/jacc-case-reports

About the journal

Abstract

Keywords